Contineum Therapeutics, Inc. Class A Common Stock (CTNM) Financial statements

Company Profile

Income Income Statement

Balance Balance Sheet

Cash Cash Flow

Absolute

YoY%QoQ% (e.g. Q3 vs Q2)

QoQ% (e.g. Q3 2020 vs Q3 2019)

Quarterly


Total Revenue
Cost of Revenue
Gross Profit
Gross Profit Margin (%)
R&D Expense
SG&A Expense
Total Operating Expenses
Operating Income or Loss
Operating Margin (%)
Interest Expense
Total Other Income/Expenses
Income Before Tax
Income Tax Expense
Income from Continuing Ops.
Net Income
Net Profit Margin (%)
Net Income Available to Common Shareholders
Basic EPS
Diluted EPS
Basic Average Shares
Diluted Average Shares

		Sep 2024	Jun 2024	Mar 2024
Total Revenue
Cost of Revenue
Gross Profit
Gross Profit Margin (%)
R&D Expense
SG&A Expense
Total Operating Expenses
Operating Income or Loss
Operating Margin (%)
Interest Expense
Total Other Income/Expenses
Income Before Tax
Income Tax Expense
Income from Continuing Ops.
Net Income
Net Profit Margin (%)
Net Income Available to Common Shareholders
Basic EPS
Diluted EPS
Basic Average Shares
Diluted Average Shares


Current Assets
Cash & Cash Equivalents
Marketable Securities
Receivables
Inventories
Other Current Assets
Total Current Assets
Non-Current Assets
Marketable Securities
PPE Net
Intangibles inc. Goodwill
Other Non-Current Assets
Total Non-Current Assets
Total Assets
Current Liabilities
Accounts Payable
Deferred Revenues
Debt, Current
Accrued Liabilities
Other Current Liabilities
Total Current Liabilities
Non-Current Liabilities
Deferred Revenues
Debt, Non-Current
Other Non-Current Liabilities
Total Non-Current Liabilities
Total Liabilities
Shareholders' Equity
Common Stock
Additional Paid-In Capital
Retained Earnings
Other Shareholders' Equity
Total Shareholders' Equity
Total Liabilities & Shareholders' Equity

		Sep 2024	Jun 2024	Mar 2024
Current Assets
Cash & Cash Equivalents
Marketable Securities
Receivables
Inventories
Other Current Assets
Total Current Assets
Non-Current Assets
Marketable Securities
PPE Net
Intangibles inc. Goodwill
Other Non-Current Assets
Total Non-Current Assets
Total Assets
Current Liabilities
Accounts Payable
Deferred Revenues
Debt, Current
Accrued Liabilities
Other Current Liabilities
Total Current Liabilities
Non-Current Liabilities
Deferred Revenues
Debt, Non-Current
Other Non-Current Liabilities
Total Non-Current Liabilities
Total Liabilities
Shareholders' Equity
Common Stock
Additional Paid-In Capital
Retained Earnings
Other Shareholders' Equity
Total Shareholders' Equity
Total Liabilities & Shareholders' Equity


Cash Flows from Operating Activities
Net Income
Depreciation & Amortization
Deferred Income Taxes
Stock Based Compensation
Accounts Receivable
Inventory
Accounts Payable
Deferred Revenue
Other Non-Cash
Operating Cash Flow
Cash Flows from Investing Activities
PPE Investments
Net Acquisitions
Purchase of Investments
Sale of Investments
Other Investing Activity
Investing Cash Flow
Cash Flows from Financing Activities
Debt Issued
Proceeds from Debt Repayment
Debt Repayment
Proceeds from Sale of Equity
Equity Repurchased
Dividend Paid
Other Financing Activity
Financing Cash Flow
Cash Position
Beginning Cash Position
End Cash Position
Change in Cash
Free Cash Flow
Operating Cash Flow
Capital Expenditure
Free Cash Flow

		Sep 2024	Jun 2024	Mar 2024
Cash Flows from Operating Activities
Net Income
Depreciation & Amortization
Deferred Income Taxes
Stock Based Compensation
Accounts Receivable
Inventory
Accounts Payable
Deferred Revenue
Other Non-Cash
Operating Cash Flow
Cash Flows from Investing Activities
PPE Investments
Net Acquisitions
Purchase of Investments
Sale of Investments
Other Investing Activity
Investing Cash Flow
Cash Flows from Financing Activities
Debt Issued
Proceeds from Debt Repayment
Debt Repayment
Proceeds from Sale of Equity
Equity Repurchased
Dividend Paid
Other Financing Activity
Financing Cash Flow
Cash Position
Beginning Cash Position
End Cash Position
Change in Cash
Free Cash Flow
Operating Cash Flow
Capital Expenditure
Free Cash Flow

Download data

Beta Financial statements are in beta. Read the caveats.